Our research group specializes in studying the pathophysiological processes of cardiovascular diseases, particularly dilated cardiomyopathy and atherosclerosis. We are a translational group composed of clinical and basic researchers. Our current lines of work focus on developing a tool based on the molecular signature of non-coding RNAs in combination with clinical and echocardiographic variables, which will enable the early identification of patients with dilated cardiomyopathy, the most common cause of heart failure with a prevalence of 1 in 250. We are also addressing the clinical need to identify patients with statin intolerance and high vascular risk. The main objective of this line of research is to characterize the molecular mechanisms involved in the muscle damage that occurs in these patients, thereby identifying new therapeutic alternatives to reduce high cholesterol concentrations. For both lines of research, we combine research strategies in cellular models (cardiomyocytes, muscle cells), studies in patients (with dilated cardiomyopathy of different etiologies, statin intolerance, and high cardiovascular risk), and the development of ex vivo assays with samples from these patients.